Open Access

Inhibition of miR‑96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1

  • Authors:
    • Tingrui Ge
    • Ping Xiang
    • Haibing Mao
    • Shumin Tang
    • Jinyi Zhou
    • Yonggang Zhang
  • View Affiliations

  • Published online on: June 25, 2020     https://doi.org/10.3892/etm.2020.8936
  • Pages: 2134-2140
  • Copyright: © Ge et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC) is one of the major threats to human health worldwide. In the treatment of CRC, chemoresistance affects the efficacy of platinum‑based therapies. Oxaliplatin is one of the most commonly used first‑line medications for the treatment of CRC; however, chemoresistance is common among patients receiving oxaliplatin treatment, which significantly decreases its therapeutic efficacy. The present study focused on the roles of microRNA (miR)‑96 in the oxaliplatin resistance of CRC cells and the underlying mechanisms. First, the expression of miR‑96 was compared between CRC and adjacent tissues. Furthermore, target genes of miR‑96 were predicted, and a dual‑luciferase reporter assay was employed to confirm whether the candidate tropomyosin 1 (TPM1) is a direct target of miR‑96. In addition, CRC cells were transfected with miR‑96 inhibitor, miR‑negative control, small interfering RNA (siRNA) targeting TPM1 or siRNA NC, and then treated with oxaliplatin. CCK‑8 assay and flow cytometry were performed to examine the proliferation and apoptosis of the CRC cell line SW480. Next, reverse transcription‑quantitative PCR and western blot analysis were performed to determine the mRNA and/or protein levels of miR‑96, Bcl‑2, BAX and TPM1. The results indicated that miR‑96 was upregulated in CRC compared with normal adjacent tissues, while TPM1 was downregulated. The luciferase activity was reduced following transfection with miR‑96 mimics and luciferase reporter plasmid containing the wild‑type sequence of the 3'‑untranslated region of TPM1. Furthermore, knockdown of miR‑96 combined with oxaliplatin reduced the viability and induced apoptosis of CRC cells, which was further verified by decreased expression of Bcl‑2 and the increased expression of TPM1 and BAX. Taken together, the downregulation of miR‑96 enhanced the sensitivity of CRC cells to oxaliplatin.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ge T, Xiang P, Mao H, Tang S, Zhou J and Zhang Y: Inhibition of miR‑96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1. Exp Ther Med 20: 2134-2140, 2020
APA
Ge, T., Xiang, P., Mao, H., Tang, S., Zhou, J., & Zhang, Y. (2020). Inhibition of miR‑96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1. Experimental and Therapeutic Medicine, 20, 2134-2140. https://doi.org/10.3892/etm.2020.8936
MLA
Ge, T., Xiang, P., Mao, H., Tang, S., Zhou, J., Zhang, Y."Inhibition of miR‑96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1". Experimental and Therapeutic Medicine 20.3 (2020): 2134-2140.
Chicago
Ge, T., Xiang, P., Mao, H., Tang, S., Zhou, J., Zhang, Y."Inhibition of miR‑96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1". Experimental and Therapeutic Medicine 20, no. 3 (2020): 2134-2140. https://doi.org/10.3892/etm.2020.8936